Stockscreener 앱 받기
7.74
1.40%
-0.11
Helus Pharma Inc 주식(HELP)의 최신 뉴스
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq - Yahoo Finance
Assessing Cybin’s Valuation As Helus Pharma Uplists To Nasdaq And Joins The Nasdaq Composite Index - Sahm
Helus Pharma Rings the Opening Bell - Nasdaq
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on NasdaqBERNAMA - BERNAMA - Malaysian National News Agency
Helus Pharma Rebrands, Debuts On Nasdaq - bernama
HELUS PHARMA REBRANDS, DEBUTS ON NASDAQ - bernama
Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - 富途牛牛
Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs - TipRanks
Cybin launches $100 million at-the-market equity program By Investing.com - Investing.com India
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks
Cybin to rebrand as Helus Pharma and shift US listing to Nasdaq - MSN
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq - TipRanks
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Yahoo Finance
Cybin to transfer listing from NYSE American to Nasdaq, rebrand - Investing.com
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Business Wire
Cybin to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire
Cybin to Participate at the 2025 Milken Institute Future of Health Summit - Business Wire
Cybin Announces $175 Million Registered Direct Offering - Business Wire
Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - Business Wire
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
Cybin Announces Senior Leadership Changes - Business Wire
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Business Wire
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Business Wire
CYBNCybin Inc Latest Stock News & Market Updates - Stock Titan
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights - Business Wire
CYBN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Cybin Inc: Paradigm Changing Ambitions (NYSE:CYBN) - Seeking Alpha
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - Business Wire
Cybin Inc: Another High-Risk Psychedelics Play (NYSE:CYBN) - Seeking Alpha
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million - Business Wire
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder - Business Wire
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses - Business Wire
Cybin to Acquire Small Pharma Inc. - Business Wire
Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics - Business Wire
Cybin Corp Announces Doug Drysdale as Chief Executive Officer - Business Wire
Cybin Corp Announces Partnership with the Toronto Centre for Psychedelic Science - Business Wire
4.73%
0.92%
자본화:
|
볼륨(24시간):